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Iron deficiency is common in patients with chronic heart failure (CHF) and is associated with reduced exercise performance, impaired
health-related quality of life and an increased risk of mortality, irrespective of whether or not anaemia is present. Iron deficiency is a serious
but treatable condition. Several randomized controlled clinical trials have demonstrated the ability of intravenous (IV) iron, primarily IV
ferric carboxymaltose (FCM), to correct iron deficiency in patients with heart failure with reduced ejection fraction (HFrEF), resulting in
improvements in exercise performance, CHF symptoms and health-related quality of life. The importance of addressing the issue of iron
deficiency in patients with CHF is reflected in the 2016 European Society of Cardiology (ESC) heart failure guidelines, which recognize
iron deficiency as an important co-morbidity, independent of anaemia. These guidelines recommend that all newly diagnosed heart failure
patients are routinely tested for iron deficiency and that IV FCM should be considered as a treatment option in symptomatic patients with
HFrEF and iron deficiency (serum ferritin <100 μg/L, or ferritin 100–299 μg/L and transferrin saturation< 20%). Despite these specific
recommendations, there is still a lack of practical, easy-to-follow advice on how to diagnose and treat iron deficiency in clinical practice.
This article is intended to complement the current 2016 ESC heart failure guidelines by providing practical guidance to all health care
professionals relating to the procedures for screening, diagnosis and treatment of iron deficiency in patients with CHF.
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Iron deficiency in heart failure is
common, important and treatable
Iron deficiency is a common co-morbidity in patients with chronic
heart failure (CHF) and can exist with or without anaemia.1 As
many as ∼40–70% of patients with CHF are iron-deficient.2–7
Iron deficiency can be described as being either ‘absolute’ or
‘functional’.8 Absolute iron deficiency is the result of reduced iron
stores [haemoglobin (Hb) and ferritin, present mainly in the liver,
spleen and bone marrow].9 In patients with CHF, iron stores may
be depleted by malabsorption, malnutrition, and gastrointestinal
blood loss (may be caused or exacerbated by the use of anticoagu-
lants, antithrombotics, or non-steroidal anti-inflammatory drugs).9
Functional iron deficiency is a result of impaired iron mobilization
from storage sites. Patients with CHF usually have systemic chronic
inflammation and elevated inflammatory cytokines, which increase
hepcidin production by the liver. Hepcidin blocks iron absorption
from the gastrointestinal tract and also iron mobilization from
storage sites, including the reticuloendothelial system.9–11 In addi-
tion, existing co-morbidities (e.g. renal dysfunction) and/or dietary
restrictions (e.g. meat-free diet) may contribute further to the
development of iron deficiency in patients with CHF.12
The physiological impact of iron deficiency extends beyond
impairment of erythropoiesis and the associated risk of anaemia.
Non-haematopoietic tissues, including skeletal and cardiac mus-
cle, are dependent on iron as the key constituent of proteins
involved in vital cellular processes, such as oxygen storage (as
the component of myoglobin) and oxidative energy metabolism
(as a component of oxidative enzymes and mitochondrial res-
piratory chain proteins).13,14 Clinical studies in patients with
CHF show that iron deficiency is associated with decreased
exercise performance,4,15–17 impaired health-related quality of life
(QoL)18,19 and an increased risk of morbidity20 and mortality,2,4,21
irrespective of the presence of anaemia.
Iron deficiency is a treatable condition. Data from randomized
clinical trials performed in patients with heart failure with reduced
ejection fraction (HFrEF) and iron deficiency have demonstrated
improvements in exercise capacity andQoL, and a reduction in hos-
pitalizations following treatment with intravenous (IV) iron.22–26
The clinical benefit of treating iron deficiency in patients with
CHF is reflected in the latest 2016 European Society of Cardiology
(ESC) guidelines for heart failure (HF), in which iron deficiency is
recognized as an important co-morbidity, independent of anaemia,
and specific recommendations relating to its diagnosis and treat-
ment are provided.1
Despite these guideline recommendations, iron deficiency is still
under-diagnosed and under-treated in clinical practice.27,28 There-
fore, many patients are being denied therapy that may potentially
have a positive impact on both cardiovascular function and QoL.
This may be partially due to the lack of practical advice on how to
screen, diagnose and treat iron deficiency. In recognition of the lack
of practical recommendations, a global working group of physicians
with expertise in this field decided to address this clinical need. This
article is intended to complement the 2016 ESC HF guidelines by
providing practical guidance for all health care professionals (HCPs)























































































Practical recommendations complementing ESC guidelines have
previously been developed for the management of other treat-
ments in CHF (e.g. angiotensin-converting enzyme inhibitors and
angiotensin II receptor blockers).29,30 The practical recommenda-
tions outlined in this manuscript were developed, discussed and
agreed by the authors during a series of working group meetings
that took place in 2016 and 2017. This practical guidance addresses
the management of patients with iron deficiency in a stepwise man-
ner, from initial screening and diagnosis through to treatment and
follow-up.
Practical recommendations
on the screening and diagnosis
of iron deficiency in patients
with heart failure
The current 2016 ESC HF guidelines1 recommend that evaluation
of iron status should be considered in the diagnostic work-up
of all newly diagnosed HF patients (class of recommendation I,
level of evidence C). A practical recommendation of the working
group is that iron status should also be evaluated in patients with
existing CHF, particularly if they are symptomatic despite receiving
optimal background HF medications. In addition, as part of routine
follow-up, consideration should be given to the re-evaluation of
iron status 1–2 times per year, as well as after hospitalization
for HF.
Ferritin and transferrin saturation (TSAT) are widely available
blood markers for evaluating iron status. Their use for the diag-
nosis of iron deficiency is recommended by the 2016 ESC HF
guidelines.1 Ferritin is an intracellular iron-storage protein secreted
by iron-storing tissues (e.g. liver and reticuloendothelial system).
Serum ferritin concentrations are a surrogate marker of stored
iron quantity.9 TSAT (defined as % of transferrin that has iron bound
to it) is used as a marker of the availability of circulating iron to
supply metabolizing cells.9 TSAT value is calculated by dividing the





The 2016 ESC HF guidelines recommend treating iron deficiency
based on a serum ferritin level<100 μg/L, or 100–299 μg/L when
TSAT < 20%. Two different cut-offs are used because ferritin lev-
els may become elevated in the presence of inflammation and may,
therefore, appear to be within the normal range (100–300 μg/L).
As ferritin, an acute-phase protein, is elevated as a result of inflam-
mation, TSAT levels < 20% indicate that insufficient circulating iron
is available to supply metabolizing cells (functional iron deficiency).9
Therefore, in accordance with the 2016 ESC HF guidelines, it is
© 2018 The Authors
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important to ensure that both ferritin and TSAT testing is per-
formed simultaneously and evaluated together when assessing iron
status (Figure 1). Lower ferritin cut-offs (e.g. < 30 μg/L) may be
used to confirm the presence of iron deficiency in other disease
settings and are often displayed on laboratory test results as the
lower limit of normal. However, the thresholds defined above are
recommended to diagnose iron deficiency in patients with CHF.
Note that mean corpuscular volume, mean corpuscular Hb
(MCH) and MCH concentration have been found to be unreliable
markers of iron deficiency status.31 Measuring their levels is not
recommended for assessment of iron deficiency in patients with
HF. In addition, serum iron concentrations can vary substantially
between HF patients, and also exhibit large diurnal variations and,
therefore, serum iron alone should not be used as a marker of iron
status.32 Ferritin and TSAT should be used instead.
In patients who are both iron-deficient and anaemic, it is impor-
tant to investigate the underlying causes of reduced Hb levels and
to exclude other pathologies, including occult blood loss. Measure-
ment of Hb levels is important as this has implications for IV iron
dosing (discussed in the next section).
Practical recommendations
on the treatment of iron
deficiency in patients with
chronic heart failure
The current treatment options for the correction of iron deficiency
in the general population consist of IV or oral iron. The 2016
ESC HF guidelines specifically recommend that, in patients with
symptomatic HF (HFrEF), iron deficiency is treated with IV ferric
carboxymaltose (FCM).1 This recommendation is based on clinical
trial evidence demonstrating the benefit of IV FCM therapy in this
patient population. In turn, oral iron therapy has been found to be
ineffective for replenishment of iron stores and improvement of
clinical status in patients with CHF (further details below).33
Intravenous iron therapy
Of the IV iron preparations licensed for therapeutic use, IV FCM
has been most extensively studied for the treatment of iron
deficiency in patients with HFrEF. The efficacy of FCM has been
evaluated in several randomized clinical trials, including FAIR-HF,22
CONFIRM-HF24 and EFFECT-HF,34 which enrolled symptomatic
patients with stable CHF [left ventricular ejection fraction (LVEF)
≤45%] and iron deficiency (Table 1).
The FAIR-HF study found that, compared with placebo, FCM
therapy was associated with significant improvements in patient
self-reported QoL (measured using patient self-reported global
assessment) and HF symptoms [measured by New York Heart
Association (NYHA) class] over a 6-month period, irrespective of
anaemia status.
The CONFIRM-HF study followed patients for 52weeks. The
primary endpoint — demonstrating that FCM therapy was associ-




















































































Figure 1 Algorithm for screening/diagnosis and treatment/
follow-up of iron deficiency in patients with chronic heart fail-
ure. Hb, haemoglobin; HFrEF, heart failure with reduced ejec-
tion fraction; IV, intravenous; NYHA, New York Heart Asso-
ciation; TSAT, transferrin saturation†. *Note: The use of ferric
carboxymaltose has not been studied in children, and there-
fore is not recommended in children under 14 years. For full
prescribing information, please refer to the Summary of Prod-
uct Characteristics.39 †TSAT= (serum iron concentration/total
iron-binding capacity) x100. Algorithm adapted from McDonagh
and Macdougall.12
using the 6-minute walk test) after 24weeks — was met. A sec-
ondary endpoint analysis found that FCM also reduced the risk of
hospitalization in patients with CHF, compared with placebo.
© 2018 The Authors
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The open-label, randomized EFFECT-HF study evaluated the
impact of FCM vs. standard of care on exercise capacity [assessed
by change in peak oxygen uptake (VO2) to week 24] in 174
patients with stable CHF and iron deficiency. After 24weeks, FCM
treatment was associated with a significantly beneficial effect on
peak VO2, vs. standard of care, in the primary analysis. This was
observed in both anaemic and non-anaemic patients.34
Based on the data from FAIR-HF,22 CONFIRM-HF24 and a
meta-analysis of randomized clinical trials26 that evaluated the
impact of IV iron therapy in patients with HFrEF, the current
2016 ESC HF guidelines recommend the use of IV FCM for the
treatment of iron deficiency in CHF (class of recommendation
IIa, level of evidence A). Furthermore, a recent meta-analysis of
individual patient data has demonstrated a reduction in recurrent
cardiovascular hospitalizations and cardiovascular mortality with IV
FCM in systolic HF patients with iron deficiency.35 The subsequent
sections will provide some practical guidance relating to the use of
IV FCM for the treatment of iron deficiency in patients with CHF.
Oral iron
Oral iron therapy is frequently used as a first-line treatment in the
correction of iron deficiency in patients with CHF. However, there
is a lack of clinical data supporting its efficacy for use in this setting.
A recent randomized, placebo-controlled clinical trial
(IRONOUT HF) evaluated the impact of high-dose oral iron
polysaccharide on exercise capacity (assessed by change in peak
VO2 from baseline to week 16) and HF symptom improvement
in patients with HFrEF and iron deficiency.33 The study found
that oral iron minimally replenished iron stores in this patient
population, compared with placebo, and did not improve exercise
capacity or HF symptoms. The results of the IRONOUT HF study
do not support the use of oral iron therapy for the correction
of iron deficiency in patients with HFrEF. There have been no
randomized controlled trials where IV iron has been compared
directly with oral iron in patients with CHF.
Furthermore, oral iron is poorly tolerated in patients with
CHF, with gastrointestinal side effects occurring in up to 60%
of patients.12 The low rate of iron absorption from oral iron
preparations means that they are less rapidly effective than IV
iron, and therefore a relatively long duration of oral iron therapy
(in some cases > 6months) may be required to achieve iron
repletion.12
Which patients are suitable candidates
for intravenous iron?
The FAIR-HF, CONFIRM-HF and EFFECT-HF studies enrolled
CHF patients with LVEF ≤ 45%, and demonstrated the efficacy
of IV FCM with respect to improving functional capacity, HF
symptoms and health-related QoL,22,24,34 while potentially reducing
risk of HF-related hospitalizations in this patient population.24
These clinical trials were not designed for, or powered to, evaluate
the effect of treatment on survival. Therefore, the potential efficacy
of IV iron therapy in reducing mortality in CHF patients has



















































































.. iron therapy has not yet been established in acute HF, or in HF
with preserved ejection fraction (HFpEF, defined as LVEF ≥ 50%).
These gaps in knowledge are being addressed in ongoing clinical
trials.36–38
Contraindications for the use of FCM in patients with CHF
and iron deficiency are few and include: hypersensitivity to the
active substance, to FCM, or any of its excipients; known serious
hypersensitivity to other parenteral iron products; the presence
of anaemia not attributed to iron deficiency (e.g. other microcytic
anaemia); evidence of iron overload; or disturbances in the utiliza-
tion of iron39 (Table 2).
It is also important to note that the efficacy and safety of IV FCM
have not been evaluated in patients with Hb levels >15 g/dL, and
therefore the drug should not be used in this patient population.
Furthermore, IV iron should be used with caution in patients with
acute or chronic infection according to the opinion of the treating
physician, and treatment with IV FCM should be stopped in patients
with ongoing bacteraemia.39
Who can administer intravenous ferric
carboxymaltose therapy?
A range of HCPs, including the general practitioner, nurse and hos-
pital physician, can administer IV FCM therapy. In clinical practice,
this varies between treatment centre and country based on local
prescribing regulations or laws. FCM can be administered in any
health care setting where staff are trained and equipment is avail-
able to evaluate and treat a potential hypersensitivity reaction. The
risk of hypersensitivity reactions with IV FCM is low, with a fre-
quency (events/patients treated) of ≥ 0.1% to <1.0% observed
during clinical trials and post-marketing surveillance.39 This is in
contrast to the historical risk of older IV iron preparations (e.g.
iron dextran), for which an increased risk of anaphylaxis has been
observed.40
How to administer and monitor
intravenous ferric carboxymaltose
therapy?
Ferric carboxymaltose contains 50mg iron/mL. A 2mL ampoule
contains 100mg of iron and a 10mL ampoule contains 500mg of
iron. The determination of the initial iron need is calculated based
on body weight and Hb levels, rather than ferritin or TSAT levels
(used to diagnose the presence of iron deficiency) (Figure 1). The
maximum recommended cumulative dose of FCM is 1000mg iron
(20mL FCM)/week.
Intravenous FCM can be given as an injection or infusion. It is eas-
ily administered as an undiluted slow bolus injection (100mg/min,
or 15min for a 1000mg dose). Note that if administered as an IV
infusion, FCM should not be over-diluted as this affects the stability
of the drug. A dilution plan of FCM for IV infusion is displayed in
Table 3. Patients should be observed for adverse effects for at least
30min following each IV injection.
After IV administration of the correction dose, we recommend
that iron status be re-evaluated at 3months. Early re-evaluation of
© 2018 The Authors
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Table 2 Practical guidance on the treatment of iron deficiency in patients with chronic heart failure
Why screen for iron deficiency?
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1. Iron deficiency is common in CHF and is associated with reduced functional capacity, impaired quality of life and a worse prognosis,
irrespective of anaemia status
2. Clinical trials of IV iron therapy conducted in patients with symptomatic HFrEF demonstrate that correction of iron deficiency is associated
with significant improvements in exercise capacity, symptoms, health-related quality of life, and possible reductions in recurrent
hospitalizations
In whom and when to give IV iron therapy?
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Indications
1. IV FCM should be considered in symptomatic patients with chronic systolic HFrEF (LVEF <40%) and iron deficiency (class of
recommendation IIa, level of evidence A)
2. Iron deficiency can be diagnosed based on the following cut-offs: serum ferritin <100 μg/L, or serum ferritin 100–299 μg/L when TSAT†<20%
Contraindications
1. Hypersensitivity to the active substance, to FCM, or any of its excipients
2. Known serious hypersensitivity to other parenteral iron products
3. Anaemia not attributed to iron deficiency, e.g. other microcytic anaemia
4. Evidence of iron overload or disturbances in the utilization of iron
Cautions/seek specialist advice
1. Use with caution in patients with acute or chronic infection; treatment with FCM should be stopped in patients with ongoing bacteraemia
2. Patients with known drug allergies, including those with a history of severe asthma, eczema or other atopic allergies, may be at an increased
risk of hypersensitivity reaction
3. Increased risk of hypersensitivity reactions to parenteral iron complexes in patients with immune or inflammatory conditions (e.g. systemic
lupus erythematosus and rheumatoid arthritis)
4. No clinical evidence for IV FCM in patients with HFpEF (LVEF ≥ 50%) and limited clinical evidence in HFmrEF (LVEF 40–49%)
5. The efficacy and safety of IV FCM has not been evaluated in patients with Hb level>15 g/dL
Which iron preparation/route?
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1. IV iron therapy with FCM is recommended by the current 2016 ESC HF guidelines (class of recommendation IIa, level of evidence A)
2. Oral iron therapy has not been shown to be an effective treatment option for iron deficiency in patients with CHF
How should IV iron be administered?
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1. Determination of the initial iron need is calculated based on body weight and Hb levels (see dosing table in Figure 1)
2. FCM may be given intravenously as an undiluted slow bolus injection, or an infusion that requires dilution. If given as infusion, it should not be
over-diluted (see dilution plan in Table 3)
3. The maximum recommended cumulative dose of FCM is 1000mg of iron (20mL FCM)/week
4. Patients should be observed for adverse effects for at least 30min following each IV injection
Where to perform the treatment?
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1. IV FCM can be administered in the hospital or community setting, where staff are trained and equipped to monitor for and manage
hypersensitivity reactions
Monitoring of iron status
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1. Following replacement, iron status should be re-evaluated in 3months and further iron repletion provided as needed, as well as evaluation
for blood loss as indicated
2. Early re-evaluation of iron status (i.e. within 4weeks of IV iron administration) should be avoided as ferritin levels increase markedly
following IV iron administration, and cannot be used as an indicator of iron status during this time
3. Consider evaluating iron status as part of routine practice in patients with known CHF (1–2 times per year) or when symptoms remain
despite receiving optimal background HF medications
CHF, chronic heart failure; ESC, European Society of Cardiology; FCM, ferric carboxymaltose; Hb, haemoglobin; HF, heart failure; HFmrEF, heart failure with mid-range ejection
fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IV, intravenous; LVEF, left ventricular ejection fraction; NYHA,
New York Heart Association; TSAT, transferrin saturation†.
†TSAT= (serum iron concentration/total iron-binding capacity) x 100.
© 2018 The Authors
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
500mg 10mL 100mL 6min
1000mg 20mL 250mL 15min
FCM, ferric carboxymaltose; m/V, mass/volume %.
iron status (i.e. within 4weeks of IV iron administration) should be
avoided as serum levels of ferritin can increase markedly following
administration of IV iron and cannot be utilized as a marker of iron
status during this time.
Further iron repletion should be provided as needed. If there is
no response or Hb levels decrease, further investigation for other
underlying causes should be considered as clinically indicated, par-
ticularly occult blood loss. After correction of iron deficiency, as
part of routine follow-up consider re-evaluation of iron parame-
ters (ferritin and TSAT) 1–2 times per year. Iron status should be
re-evaluated if patients remain symptomatic despite receiving opti-
mal background HF medications, or in the event that Hb levels
decrease (Figure 1).
Clinical studies have demonstrated that IV FCM is well toler-
ated with an acceptable safety profile in patients with CHF.22,24
The most common side effects (occurring at a frequency of ≥ 1.0%
to <10.0%) reported during clinical trials and post-marketing
surveillance include dizziness, headache, hypertension, hypophos-
phataemia, injection-site reactions, and nausea.39 In patients who
are iron-deficient and anaemic, appropriate investigation to deter-
mine the underlying cause of anaemia and to exclude other
pathologies based on local clinical practice guidelines should be
implemented as a safety measure. The risk of hypersensitivity
reactions with IV FCM is low, with a frequency (events/patients
treated) of ≥ 0.1% to < 1.0% observed during clinical trials and
post-marketing surveillance. Skin staining (or discolouration) can
occur at the infusion site if there is extravasation of IV iron.39 This
may be avoided by ensuring best practice in IV line placement and
care. In case of paravenous leakage, the administration of FCM
must be stopped immediately.39
Conclusions
There is evidence from randomized clinical trials to show that
correction of iron deficiency with IV iron therapy in patients with
CHF (LVEF ≤ 45%) provides improvements in functional capacity,
HF symptoms and health-related QoL, and may reduce the risk of
HF-related hospitalizations.22,24,34
The 2016 ESC HF guidelines recommend that iron status should
be evaluated as part of the initial work-up of all newly diagnosed
HF patients.1 The working group also recommends that iron status
is checked among patients with existing CHF independently of
Hb level or when symptoms persist despite receiving optimal



































































. Intravenous iron therapy with FCM is recommended by the
2016 ESC HF guidelines for the correction of iron deficiency, and
should be considered in symptomatic patients with HFrEF and iron
deficiency.1
Knowledge gaps and areas
for further research
It is important to note that, in the absence of certain clinical data,
some of the practical recommendations made in this article are
based on the collective expert opinion of the working group.
As outlined in the article, several knowledge gaps relating to
the role of IV iron therapy in HF patients remain, many of which
are being addressed by ongoing randomized clinical trials. These
include the need for robust clinical data evaluating the impact
of IV iron therapy on morbidity and mortality in systolic CHF
patients with iron deficiency; these will be provided by the ongo-
ing FAIR-HF2 (NCT03036462) and IRONMAN (NCT02642562)
studies. Furthermore, the efficacy and safety of IV iron has not
yet been established in patients with HFpEF or acute HF and
iron deficiency — the ongoing FAIR-HFpEF (NCT03074591) and
AFFIRM-AHF (NCT02937454) studies should provide a better
insight into the role of IV iron therapy in each of these patient
populations.
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